Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine ( - Article Discussing Pharmacokinetics a...)

Labopharm to Present Poster on Dose Titration of Once-daily,Tramadol at 3rd International Forum on Pain Medicine

- Article Discussing Pharmacokinetics and Dose Proportionality of Company's Once-Daily Tramadol to be Published in Biopharmaceutics Journal -

LAVAL, QC, June 29, 2007 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that it will present a poster discussing the dose titration of its once-daily formulation of tramadol at the 3rd International Forum on Pain Medicine to be held June 28 to July 1, 2007 in Montreal, Canada.

The poster compares two different titration schedules for Labopharm's once-daily formulation of tramadol in three Phase III clinical trials: a six-day titration to a 300 mg dose (clinical trials MDT3-002 and MDT3-003) and a nine-day titration to a 300 mg dose (clinical trial MDT3-005). The comparison showed that percentage of adverse events and discontinuations due to adverse events was similar regardless of the titration schedule.

These results, in addition to the fact that Labopharm's once-daily tramadol formulation achieves steady state plasma levels after two days, suggest that a shorter titration schedule may be adequate for most patients. A previous study showed that most patients achieve pain control using Labopharm's once-daily tramadol at a dose of 200 mg. The data in this poster suggest that, for most patients, after starting with a dose of 100 mg for two days, the therapeutic dose of 200 mg could be achieved after two days without increased risk of side effects. If a patient requires a higher dose (300 mg), the therapeutic dose could be achieved after six days of titration (100 mg for 2 days; 200 mg for 3 days then 300 mg on the 6th day) without increased risk of side effects.

"The results of the comparison of titration periods reviewed in the poster suggest that patients may benefit from rapid titration to optimal analgesia without increased risk of side effects using our product," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm
'"/>

Page: 1 2 3
Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference

Post Your Comments:

(Date:5/16/2013)... N.C. , May 16, 2013 Today, the ... North Carolina House of Representatives recently approved ... for chemotherapy from charging patients higher out-of-pocket fees for ... formularies, many of which have more severe side-effects. However, ... limit of $300, which will continue to be a ...

(Date:5/16/2013)... -- Alere Inc. (NYSE: ALR ), a global leader ... home through the merger of rapid diagnostics and health management, ... its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). The ... record of Series B stock at the close of business ... the amount of all dividends accrued from April 1, 2013 ...

(Date:5/16/2013)... Calif. , May 16, 2013 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies for ... Richard King , President and CEO, will ... at the Sheraton New York Hotel in New ... May 22, 2013 at 9:30 a.m. ET/6:30 a.m. PT. ...

Breaking Medicine Technology:National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2 National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3 AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 2 AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference 3

[0] National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill [0] Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock [0] AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference

... genomics, SAN DIEGO, April 14 Systems ... Inc. (CTI) (Nasdaq,and MTAX: CTIC), presented data from ... more likely to respond to treatment with the,experimental ... Research (AACR) annual meeting. These findings will be ...

... During Wednesday,s Satellite Symposium,3: The Challenges of ... the,International Society of Heart and Lung Transplantation ... researchers discussed some of,the unique challenges in ... CF., A highlight of the session ...

Cached Medicine Technology:New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 2 New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 3 New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 4 New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit 5 Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2 Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3

New Gene Discovery Suggests Which Patients CTI's Brostallicin May Benefit Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting

(Date:5/19/2013)... IL (PRWEB) May 19, 2013 In partnership ... LLC, E-dentist.com has announced the launch of an SEO website ... dentists get high rankings in Google. , http://www.e-dentists.com/ ... not pay for the service until they see results. Dentists ... The lead generation websites run by JD Media Surge, LLC ...

(Date:5/19/2013)... (PRWEB) May 19, 2013 Grinding your ... just losing sleep, or annoying your spouse. At the ... by CNY Central (“Snoring and Teeth Grinding Could Be ... of teeth grinding can be hard to prevent. Apparently, ... Americans, and one of its symptoms is a habit ...

(Date:5/19/2013)... The report “Feed Additives Market by Types, Livestock ... 2017” published by MarketsandMarkets, defines and segments the global ... the global volume and revenue for the animal feed ... for the global market with analysis of trends, opportunities, ... segmented and revenue is forecasted on the basis of ...

(Date:5/19/2013)... May 19, 2013 Farming methods have ... in the ground 10,000 years ago. Most recently, the ... productivity by using genetically engineered seeds and by applying ... a backlash to these techniques due to the adverse ... and a corresponding surge in interest in organic, sustainable ...

(Date:5/19/2013)... Yeast infections are common in both men and women. ... human body. A new yeast infection treatment product has been ... method of application to help eliminate over growth of the ... men and women searching for a natural process of yeast ... food and is stored in the intestines. In small consumable ...

Breaking Medicine News(10 mins):Health News:Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC 2 Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 2 Health News:Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder 3 Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 2 Health News:Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets 3 Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 2 Health News:Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics 3 Health News:A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount 2

[0] Effective New Dental SEO Solution Launched by E-dentists.com in Partnership with JD Media Surge, LLC [0] Dr. Kanani, Woodland Hills Dentist: Dangers of Tooth Damage and Obstructive Sleep Disorder [0] Feed Additives Market to Reach $19.5 Billion by 2017 at a CAGR of 3.8% - New Report by MarketandMarkets [0] Green Acre Aquaponics Introduces a Revolutionary Approach to Farm Education and Commercial Aquaponics [0] A Safe & Homeopathic Yeast Infection Relief by Yeastrol Now Available at HealthCareSupplementz.com with Massive Discount

... ... enrollment grew by 708,000 members during 2007, - Selling, general and administrative expense ratio continued to improve, ... Operating cash flow exceeded $4.3 billion for the year, or 1.3 times net ... income, - Company reiterates diluted earnings per share target of $6.41 for ...

... Mentally Fit Years Longer, KIRKLAND, Wash., Jan. 23 ... people need long term care today," says Cameron,Truesdell, CEO ... care insurance agency. "That shouldn,t be, so we,re going ... To that end, the,company is offering a free guidebook ...

... Approval for Gestiva(TM) Anticipated in Calendar 2008, Gestiva(TM), is ... the Prevention ... Birth in Singleton Pregnancies, ST. LOUIS, Jan. 22 ... pharmaceutical company that,develops, manufactures, acquires and markets technology-differentiated,branded and ...

... Group of Lawmakers Vow to Fight Premature Birth in Ohio, ... and Ohio,s rate of premature birth is up once again ... 19,321 preterm births were recorded for,2005 and over 20 lawmakers ... of Ohio,s babies. "We were happy to receive the news ...

... cleaners with the hospital laundry, FORT WORTH, Texas, Jan. ... Huguley Memorial Medical Center after,the hospital staff sent their newborn ... July 8, 2007, Kourtney McGee gave birth to her son, ... was taken to the,hospital morgue., As Ms. McGee and ...

... Sargent of Success Design International, to offer a new course in ... ... The business of,life coaching takes another step forward with the Hemispheric,Integration(TM) ... science of personal achievement. It is an art,because the way each person ...

WellPoint Reports Fourth Quarter and Full Year 2007 Results Long Term Care Insurance Leader Offers Advice on Preventing Dementia, the Leading Cause of Care Claims KV Pharmaceutical Company Announces Acquisition of Rights to Gestiva(TM)Ohio Prematurity Caucus Forming to Meet Challenge A Fort Worth Couple Sues Huguley Memorial Medical Center Spencer Institute Offers a Home-Training Course for Hemispheric Integration & Neuro-linguistics Coach Certification

GP8R is a powerful 3-liter large capacity centrifuge which is flexible and easy to use with refrigeration facility. Performs separations 50-100% faster than the rest, powerful, accommodating and conv...

... Rotanta 460 family of ... line that meets a ... They feature high capacity, ... state-of-the-art technology and high ...

... 15 centrifuge provides all the ... for today's full-service clinical lab ... a speed up to 15,300 ... spin tubes, plates and rotors ...

BD Dynac III is a general purpose centrifuge. Digitally precise variable speeds, microprocessor controlled, versatile rotor choices, user programmable: speed, RCF and time, 10 program (memory) settin...

Medicine Products:

Centra-GP8R Rotanta 460R Spinchron 15 Refrigerated Centrifuge Dynac III